Stock ABCL ABCELLERA BIOLOGICS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases AbCellera Biologics Inc.

Equities

ABCL

CA00288U1066

Real-time Estimate Cboe BZX
Other stock markets
 17:22:11 06/05/2024 BST 		5-day change 1st Jan Change
4.085 USD +1.36% Intraday chart for AbCellera Biologics Inc. +6.38% -28.46%
05-01 AbCellera Biologics Inc., Viking Global Investors, and ArrowMark Partners Collaborate to Launch New Biotech Companies CI
03-11 AbCellera, Biogen Collaborate to Discover Treatments for Neurological Diseases MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
AbCellera, Viking Global Investors, and ArrowMark Partners Collaborate to Launch New Biotech Companies
BU
AbCellera Biologics : Corporate Overview
PU
AbCellera Presents Data on T-Cell Engagers Against Four Tumor Targets at AACR 2024
BU
AbCellera to Report First Quarter 2024 Financial Results on May 7, 2024
BU
AbCellera to Present at the Bloom Burton Healthcare Conference on April 16, 2024
BU
AbCellera to Collaborate with Biogen to Discover Therapeutic Antibodies for Neurological Conditions
BU
AbCellera Announces Four Presentations on T-Cell Engagers at AACR 2024
BU
AbCellera Announces Resignation of Board Member
AQ
AbCellera Announces Resignation of Board Member
BU
AbCellera to Present at Upcoming Investor Conferences in March
BU
AbCellera Reports Full Year 2023 Business Results
BU
AbCellera to Report Full Year 2023 Financial Results on February 20, 2024
BU
AbCellera to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024
BU
Cutting-edge antibody therapy firm, AbCellera, to lay off 10 per cent of workforce
AQ
AbCellera to Present at the Piper Sandler 35th Annual Healthcare Conference on November 30, 2023
BU
AbCellera Presents New Data on Two T-Cell Engager Programs at SITC 2023
BU
AbCellera Biologics : Third Quarter 2023 Presentation
PU
AbCellera Reports Q3 2023 Business Results
BU
Prelude Therapeutics and AbCellera Enter Partnership to Develop First-in-Class Precision Antibody Drug Conjugates in Oncology
BU
Prelude Therapeutics and AbCellera Enter Partnership to Develop First-in-Class Precision Antibody Drug Conjugates in Oncology
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ABCL Stock
  4. News AbCellera Biologics Inc.
  5. Press Releases